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Abstract 
The p38 MAPK kinase pathway is activated in response to a wide range of cellular stress 
stimuli and cytokines. Our understanding of the important functions of p38 MAPK in the 
process of differentiation and cell death has grown considerably in the recent years and is 
now relatively established. Here we discuss the role of p38 MAPK in the mediation of cell 
cycle checkpoints and cell survival, processes that have received less attention. We describe 
how p38 MAPK regulates both the G2/M as well as a G1/S cell cycle checkpoint in response 
to cellular stress such as DNA damage. While p38 MAPK has classically been associated with 
the induction of apoptosis, we discuss that p38 MAPK can also mediate cell survival in spe-
cific situations, such as in response to DNA damage. It is important to recognize these less 
appreciated functions of p38 MAPK when considering the potential use of pharmacological 
inhibitors of p38 MAPK in therapeutic treatments for disease.   
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Introduction 
The family of mitogen activated protein kinases 
(MAPKs) is composed of three major groups: the ex-
tracellular regulated kinases (ERKs), the C-Jun 
N-terminal Kinases (JNKs) and the p38 MAPKs [1]. 
The p38 MAPK group consists of four members: p38α, 
p38β, p38γ and p38δ. These proteins are encoded by 
separate genes and are approximately 60% identical at 
the amino acid level. Based on their expression pat-
tern, substrate specificity and sensitivity to pharma-
logical inhibitors, they can be divided into two 
groups: p38α and p38β on the one hand and p38γ and 
p38δ on the other [2]. While p38α and p38β are uni-
versally expressed, p38γ and p38δ appear to have a 
more tissue specific expression pattern. p38γ is most 
abundant in skeletal muscle while p38δ is highly ex-
pressed in testes, pancreas, kidney and small intes-
tine. All isoforms phosphorylate the Ser-Pro or 
Thr-Pro MAPK consensus motifs, but some substrate 
selectivity has been reported. For example, the 
microtubule associated protein Tau is a better sub-
strate for p38γ and p38δ, while MAPKAP kinase-2 
(MK2) and MK3 are better substrates for p38α and 
p38β. The commonly used p38 MAPK inhibitor 
SB203580 specifically inhibits p38α and p38β, but does 
inhibit p38γ and p38δ activities.  
Loss of p38β, p38γ or p38δ does not perturb 
normal development indicating that there is some 
redundancy in function for the family members. 
However disruption of the p38α gene results in em-
bryonic death because of placental defects demon-
strating that some functions cannot be compensated 
by other family members[3-6]. p38α is the best char-




p38 MAPK and other family members will be spe-
cifically designated when discussed.  
In response to cellular stress and cytokines p38 
MAPK is activated by phosphorylation of the 
Thr-Gly-Tyr (TGY) dual phosphorylation motif. 
MAPK kinases (MKK) 3 and MKK6 are the primary 
upstream activators of p38 MAPK. In response to 
certain stimuli, MKK4 has also been shown to activate 
p38 MAPK but only in specific situations. A variety of 
upstream MAPK Kinase Kinases phosphorylate 
(MKKKs) are known to phosphorylate and activate 
the more specific MKKs [7]. p38 MAPK can also be 
activated independently of the MKKK/MKK cascade 
by autophosphorylation [8-10].  
The role of the p38 MAPK pathway in the cell 
differentiation, growth inhibition and apoptosis is 
well established and has been previously reviewed 
[ 1 1 ,  1 2 ] .  B a s e d  o n  t h e  r o l e  o f  p 3 8  M A P K  i n  t h e s e  
processes, p38 MAPK has been defined as a tumor 
suppressor. The focus of this review is on the less 
characterized functions of the p38 MAPK pathway, 
such as its role in the regulation of cell cycle check-
points and cell survival. 
Regulation of the cell cycle checkpoints by 
p38 MAPK 
In eukaryotic cells, there are evolutionarily con-
served pathways that sense and respond to various 
types of cellular stress via a series of checkpoints that 
delay the progression to the next phase of the cell cy-
cle. In response to stress stimuli that cause DNA 
damage, cells undergo cell cycle checkpoints to allow 
time for DNA repair. Two major cell cycle checkpoints 
have been characterized, a G1/S checkpoint including 
both prior to and during DNA synthesis and a G2/M 
checkpoint prior to cell division [13]. The p38 MAPK 
pathway is involved in the induction of both check-
points although its role in the G2/M checkpoint is 
better established. 
The role of p38 MAPK in the G2/M cell cycle checkpoint 
Exposure to ultraviolet light (UV), γ-irradiation 
and chemotherapeutic drugs such as etoposide results 
i n  t h e  g e n e r a t i o n  o f  D N A  d o u b l e  s t r a n d  b r e a k s  
(DSBs). In response to DSBs, p38 MAPK is activated 
and leads to the establishment of a G2/M cell cycle 
checkpoint [14, 15]. The mechanism by which DNA 
DSBs activate p38 MAPK is not completely clear. p38 
MAPK activation in response to DNA DSBs has been 
reported to be dependent on the activation of Ser/Thr 
protein kinases that serve as DNA damage sensors, 
specifically the ataxia telangiectasia-mutated (ATM) 
and ataxia telangiectasia-mutated and Rad3-related 
(ATR) kinases [16]. However while the activation of 
ATM may be required for the activation of p38 
MAPK, ATM does not appear to be able to directly 
phosphorylate p38 MAPK. Indeed the consensus mo-
tif recognized by ATM is not present in the p38 family 
members. Instead activation of p38 MAPK appears to 
be mediated by the Thousand and one (Tao) kinases 
which are directly activated by ATM. Tao kinases are 
one of the multiple MAPKKK that can activate 
MKK3/6 [17]. It should be noted that alternative 
mechanisms to the ATM/ATR pathway can also ac-
tivate p38 MAPK because activation of p38 MAPK can 
occur in the presence of the ATM inhibitor caffeine 
and in ATM knockout cell lines in response to topoi-
somerase II inhibitors and UV [15, 16]. Thus, it ap-
pears that in addition to the ATM-dependent path-
way other not yet established mechanisms activate 
p38 MAPK in response to DNA damage. The specific 
pathways connecting DNA damage to p38 MAPK 
activation may vary by cell type, the specific DNA 
damage stimuli and the extent of DNA damage.  
Regarding the mechanism by which p38 MAPK 
contributes to the induction of the G2/M cell cycle 
checkpoint two pathways have been described (Fig.1). 
p38 MAPK phosphorylates and activates p53 and this 
leads to the induction of a p53-dependent G2/M 
checkpoint [18-21]. p38 MAPK can phosphorylate 
mouse p53 at Ser18 and Ser389 (human Ser15 and Ser392, 
respectively). Phosphorylation of these residues re-
sults in the dissociation of p53 from Murine double 
minute 2 (Mdm2), a protein that binds to the transac-
tivation domain of p53 and promotes p53 ubiquitina-
tion and degradation. Disruption of this interaction 
promotes the accumulation of p53. p38 MAPK also 
associates with Growth arrest and DNA damage in-
ducible 45α (Gadd45α) proteins and promotes their 
association with p53 further increasing p53 stability 
[22, 23]. The activation and stabilization of p53 by p38 
MAPK leads to the transcription of p53-target genes 
such as Gadd45α, p21 and 14-3-3 [24-26]. These pro-
teins enforce a G2/M checkpoint by either directly or 
indirectly inactivating cdc2/cyclinB complex which is 
the major engine driving the transition from G2 to M.  
p38 MAPK can also induce a G2/M checkpoint 
through the phosphorylation and inhibition of the 
phosphatase Cdc25B [27]. Cdc25B dephosphorylates 
cdc2 and activates the CyclinB/cdc2 complex driving 
progression of the cell cycle. It has been proposed that 
phosphorylation of Cdc25B inhibits its activity by 
promoting its association with 14-3-3 proteins and 
sequestering it in the cytoplasm [28, 29]. While it was 
initially reported that p38 MAPK could directly 
phosphorylate Cdc25B in vitro, more recent studies 
have shown that p38 MAPK promoted the phos-




tion of MK2 one of the well known substrates of p38 
MAPK [30, 31]. Activation of MK2 was also shown to 
be required for the induction of a G2/M checkpoint in 
response to UV in these studies.  
As mentioned above, although similar in sub-
strate specificity, the different p38 MAPK family 
members can also mediate distinct functions. Thus all 
p38 MAPK isoforms appear to be activated in an 
ATM-dependent manner in response to γ-irradiation, 
but only p38γ seems to be required for the induction 
of the G2/M checkpoint [32]. Specific p38 MAPK iso-
forms therefore may have different roles in the induc-
tion of a G2/M checkpoint depending on the experi-
mental system.  
 
Figure 1. The role of p38 MAPK in the G2/M Checkpoint. 
The function of p38 MAPK in the G1/S cell cycle checkpoint 
Although less established, p38 MAPK activation 
can also contribute to the induction of a G1/S check-
point in response to stimuli such as osmotic stress, 
reactive oxygen species and cellular senescence. 
Similar to the G2/M checkpoint regulation, several 
mechanisms by which p38 MAPK mediates a G1/S 
checkpoint have been described. p38 MAPK can in-
duce a G1/S checkpoint through the activation of p53. 
Consistent with its role as a master regulator of the 
cell cycle, in addition to controlling the G2 to M pro-
gression, p53 also regulates G1 to S progression. p38 
MAPK activation of p53 results in the accumulation of 
p21, one of the p53 targets[33, 34]. While p21 pro-
motes a G2/M checkpoint by inactivating cdc2, to 
establish a G1/S checkpoint p21 inactivates cdk2. In 
addition, it has been reported that p38 MAPK can 
directly phosphorylate and stabilize p21 in vivo [33].  
Cyclin D binds to and actives cyclin dependent 
kinase 4 and 6 (Cdk4/6) and this active complex is 
essential for the transition to S phase and further cell 
proliferation. p38 MAPK had been shown to reduce 
the levels of cyclin D1 by two independent mecha-
nisms. p38 MAPK can negatively regulate cyclin D1 at 
the level of transcription [35]. This negative effect 
could be explained by the phosphorylation and stabi-
lization of HMG-box protein 1 (HBP1) by p38 MAPK. 
HBP1 is a transcriptional repressor that inhibits cyclin 
D1 gene expression [36]. p38 MAPK can also directly 
phosphorylate cyclin D1 and resulting in cyclin D1 
ubiquitination and proteosomal degradation [37].  
Unlike other members of the Cdc25 family that 
only regulate the G2/M transition, Cdc25A is a cy-
clin-dependent protein kinase phosphatase that can 
regulate the G1/S transition as well [38-40]. p38 
MAPK can phosphorylate and promote the degrada-
tion of Cdc25A contributing to establishment of a 
G1/S checkpoint [41].  
p16INK4a and p19ARF are two different pro-
teins encoded in the INK4a/ARF locus that regulate 
the G1/S checkpoint by two different pathways. p16 
promotes a G1/S checkpoint by inhibiting cyclin de-
pendent protein kinase Cdk4/6 activation [42], and 
p19 promotes a G1/S checkpoint by regulating p53 
function [43, 44]. p38 MAPK can also mediate a G1/S 
checkpoint by upregulating p16INK4a and p19ARF 
gene expression [45-47]. Thus, p38 MAPK can regu-
late the induction of a G1/S checkpoint by multiple 
distinct mechanisms (Figure 2).  
 




p38 MAPK and survival 
 As mentioned above, p38 MAPK was identified 
as a stress kinase because it is activated by stimuli that 
cause some kind of stress to cells, eventually leading 
to cell death. As a consequence, p38 MAPK is gener-
ally believed to be a kinase that mediates cell death. 
However, while this assumption is correct in most 
cases, cause-effect studies have also found that acti-
vation of p38 MAPK by stress stimuli may not neces-
sarily promote death, instead it enhances cell survival. 
Here we will discuss this alternative and less charac-
terized function of the p38 MAPK signaling pathway, 
and provide potential scenarios where survival in-
stead of death is the main goal of p38 MAPK activa-
tion (Figure 3).  
 
Figure 3. The role of p38 MAPK in mediating survival. 
 
  One of the common circumstances where acti-
vation of p38 MAPK has been shown to be essential 
for survival is in response to stimuli that cause a type 
of DNA damage. As discussed above, UV, 
γ-irradiation and chemotherapeutic cancer drugs are 
stimuli that damage DNA and result in cell death. 
These stimuli are also strong activators of the p38 
MAPK pathway. Thus, activation of p38 MAPK was 
observed in Jurkat T cells when treated with a com-
bination of UV and 8-methoxypsoralen (8-MOP), a 
tricyclic aromatic compound that intercalates into 
DNA and crosslinks the two strands of DNA in the 
presence of UV leading DNA damage and cell death 
[48]. However, instead of preventing death, inhibition 
of p38 MAPK with the pharmacological inhibitor in-
creased death of these cells in a dose dependent 
manner [48]. Similarly, treatment of human B cell 
lymphoma cells with etoposide, a DNA-damaging 
chemotherapeutic drug, activates p38 MAPK, but 
pharmacological and genetic inhibition of this path-
way enhances the apoptotic effect of etoposide [49]. 
Doxorubicin (topoisomerase II inhibitor) and cisplatin 
(DNA crosslinker) activate p38 MAPK and induce 
death of osteosarcoma cells. Nevertheless, down-
regulation of MK2 enhances death triggered by cis-
platin and doxorubicin [16]. Since MK2 is one of the 
major substrates of p38 MAPK in response to irradia-
tion [30], it is likely that p38 MAPK is also involved in 
the survival process of these cells through activation 
of MK2. Thus, while there is no strong evidence that 
p38 MAPK by itself induces cell proliferation and 
malignancies, in response to DNA damage stimuli 
activation of p38 MAPK in cancer cells increases cell 
survival. This could be a defense mechanism that cells 
develop to overcome the effect of cytotoxic drugs af-
fecting DNA integrity. Indeed, p38 MAPK may not be 
directly activated in response to damage, but it can be 
activated by the counterpart survival response. Si-
multaneously to DNA damage, ionizing irradiation 
also causes the activation of tyrosine kinase receptors, 
such as the insulin-like growth factor 1 receptor 
(IGF-1R) that can provide survival signals. Activation 
of p38 MAPK by IGFR1 in response to ionizing irra-
diation appears to contribute to the radioresistance 
effect provided by IGFR1 [50]. Considering the role of 
p38 MAPK in the induction of a G2/M cell cycle 
c h e c k p o i n t ,  t h e  s u r v i v a l  e f f e c t  o f  p 3 8  M A P K  i n  r e -
sponse to DNA damage could be explained by its 
effect in facilitating DNA repair prior to the continua-
tion through mitotsis, helping tumor cells to escape 
the mitotic catastrophe. In this regard, it has been 
shown that p38 MAPK contributes to resistance to 
chemotherapeutic DNA-methylating drugs by pro-
moting DNA mismatch repair and G2/M cell cycle 
checkpoint [51]. Alternatively, an active survival sig-
nal may provide advantage for cells to survive 
through the G2/M cell cycle checkpoint, properly 
repair and further expand (see below). 
  It is well known that DNA DSBs are normally 
generated in response to DNA damaging agents (e.g. 
ionizing irradiation, chemotherapeutic drugs). How-
ever, less known is the fact that DSBs are naturally 
generated in specific cells in the absence of danger 
stimuli. The expression of antigen specific T cell re-
ceptor (TCR) and B cell receptor (BCR) genes is 
unique and different to any other type of gene ex-




the multiple V, D and J DNA segments to form a 
coding gene. This process is defined as V(D)J recom-
bination and it is mediated by the T and B cell specific 
endonucleases, RAG1 and RAG2, that recognize the 
recombination signal sequences (RSSs). During the 
recombination process, RAG proteins bind to these 
sequences, bring them together and cleave DNA im-
mediately adjacent to the RSSs through the endonu-
c l e a s e  a c t i v i t y  t o  g e n e r a t e  n i c k e d  D N A .  T h e  3 ’  h y -
droxyl groups of these two nicks attack the other 
DNA strands to form two independent hairpins 
(coding ends) within the genomic DNA, while the 
double stranded breaks (DSBs) from excised frag-
ments (signal ends) remain as DSBs. Thus, DSBs are 
continuously generating in developing T and B cells. 
During the development of T cells in the thymus, re-
combination of the germ line TCRβ gene occurs at the 
double negative (DN)3 stage of thymocyte differen-
tiation. It has been shown that p38 MAPK is activated 
at this stage of T cell development, and its activation is 
dependent on the presence of RAG-mediated DSBs 
[52].  In vivo activation of p38 MAPK in these cells, 
induces a G2/M cell cycle checkpoint, but it also pro-
vides survival signals [52], and evidence that p38 
MAPK can mediate survival in the context of DNA 
damage in vivo. 
 Although less frequently reported, some studies 
have also involved p38 MAPK in survival of tumor 
cells independently of DNA damage, and suggested 
that p38 MAPK contributes to metastasis. However, 
this effect appears to be indirectly mediated by p38 
MAPK through the regulation of the secretion of fac-
tors that promote survival or migration of cells. Thus, 
basal activation of p38 MAPK in B-cell chronic lym-
phocytic leukaemia (B-CLL) is required for the ex-
pression of the MMP-9 metalloprotease that is turn is 
required for survival of these cells when cultured in 
the presence of stroma cells [53]. Decreased basal as 
well as TGFβ1-induced MMP-9 activity has also been 
found in breast cancer cells when p38 MAPK pathway 
was inhibited by genetic approaches and pharmacol-
ogical compounds, leading to decreased bone metas-
tases in vivo [54].   
p38 MAPK can also mediate cell survival in 
non-malignant cells. Early studies in PC12 neuronal 
cell line proposed that p38 MAPK mediates death in 
these cells [55]. However, it was later shown that ge-
netic inhibition of p38 MAPK promotes death of pri-
mary cerebellar granule neurons grown in vitro in 
survival conditions by the presence of a depolarizing 
dose of KCL [56]. Similar to neurons, primary cardiac 
myocytes are also excitable when treated with specific 
growth factors. Activation of p38 MAPK by expres-
sion of a constitutive active MKK6 in primary car-
diomyocytes seems to protect these cells against 
apoptosis triggered by the treatment with anisomycin 
(a protein synthesis inhibitor) [57].   
Interestingly, several studies have reported the 
r o l e  o f  p 3 8  M A P K  i n  s u r v i v a l  o f  d i f f e r e n t  t y p e  o f  
mature granulocytes. Granulocytes (e.g. neutrophils, 
eosinophils, basophils) have in common their termi-
nal differentiation stage. These cells have fragmented 
nuclei and have an accumulation of granuli contain-
ing preformed secretion factors. It has been proposed 
that p38 MAPK is required for survival of neutrophils 
during inflammation, and inactivation of p38 MAPK 
is essential for death and the elimination of these cells 
during the resolution of the inflammatory response 
[58, 59]. Similarly, inhibition of p38 MAPK appears to 
enhance constitutive apoptosis of eosinophils upon 
cytokine-deprivation (e.g. IL-5), suggesting that acti-
vation of p38 MAPK during the inflammatory re-
sponse is critical for the survival of these short life 
cells, and inactivation of this pathway is also impor-
tant for resolution of inflammation [60].  
What are the mechanisms involved in p38 
MAPK-mediated cell survival? We already described 
above that p38 MAPK can indirectly regulate survival 
by promoting the expression of survival secreted fac-
tors such as MMP-9. Although it has been proposed 
that p38 MAPK can mediate survival by phosphory-
lation of caspase 3 and caspase 8 in neutrophils [58], it 
is unlikely to be due to a direct phosphorylation by 
p38 MAPK since the identified phosphorylation site 
motifs (SL) in caspases are not consensus MAP kinase 
r e c o g n i z e d  m o t i f s  ( S P  o r  T P ) .  I n  r e s p o n s e  t o  D N A  
damage, an obvious mechanism by which p38 MAPK 
may indirectly increase survival is by inducing the 
G2/M cell cycle checkpoint and increasing the chance 
for DNA repair prior to a mitotic catastrophe. p38 
MAPK could also directly favor the DNA repair 
process since pharmacological inhibition of p38 
MAPK appears to decrease binding of the repair Ku 
proteins to DNA [50], but the mechanism remains 
unclear. 
A recent study has shown a novel mechanism by 
which p38 MAPK can directly mediate cell survival. 
β-catenin is a transcription factor known to promote 
survival by regulating the expression of other survival 
genes such as c-myc [61]. β-catenin levels are regu-
lated by a multiprotein complex containing the tumor 
suppressor adenomatous polyposis coli (APC), the 
scaffolding protein axin and GSK3β . Phosphorylation 
of β-catenin by GSK3β targets β-catenin for ubiquiti-
nation and subsequent degradation [62]. Signals that 
prevent GSK3-mediated β-catenin phosphoryla-
tion, cause an accumulation of β-catenin in the cytosol 




Previous studies have indicated that p38 MAPK can 
indirectly modulate GSK3β activity through either 
AKT or Gadd45α [64-66]. While the inactivation of 
GSK3β is normally mediated via phosphorylation of 
its N-terminus at S9 by AKT [67], a recent study has 
shown that p38 MAPK directly inactivates GSK3β by 
phosphorylation at a novel site (Ser389) in the 
C-terminus of GSK3β [68]. Phosphorylation of GSK3β 
at Ser389 by p38 MAPK inhibits GSK3β probably 
through a mechanism similar to the mechanism re-
ported for the phosphorylation at the Ser9. Thus, 
phosphorylation and inactivation of GSK3β followed 
by the accumulation of β-catenin could be a mecha-
nism by which p38 MAPK mediates survival in dif-
ferent cell types and in response to different stimuli. 
In contrast to the broadly distributed phosphorylation 
of GSK3β at Ser9, p38 MAPK-mediated phosphoryla-
tion of GSK3β at Ser389 appears to be tissue specific 
(predominantly in brain). Thus, although it has been 
proposed that p38 MAPK mediates neuronal survival 
by phosphorylation of the transcription factor MEF2 
[56], inactivation of GSK3β could be an alternative 
mechanism. It remains to be determine whether 
phosphorylation of GSK3β on Ser389 participate in 
those scenarios where p38 MAPK has already been 
shown to mediate survival, such as in tumor cells in 
response to DNA damage-inducing stimuli.  
Another proposed mechanism by which p38 
MAPK can promote survival of tumor cells is by in-
hibition of autophagy, such in the case of colon cancer 
cells [69]. Autophagy was initially identified as an 
alternative pathway for cell death other than apop-
tosis because it is a mechanism to eliminate parts of 
intracellular compartments including mitochondria 
[70]. Autophagy was shown to occur primarily in 
tumor cells, but we now know that it is a widely dis-
tributed phenomenon in primary cells as well. Some 
studies have reported that p38 MAPK inhibits the 
initiation of autophagy and, thereby, inhibits cell 
death [70]. Inhibition of p38 MAPK appears to induce 
gene expression of GABARAP, a component of the 
v a c u o l e s  f o r m e d  d u r i n g  a u t o p h a g y .  H o w e v e r ,  i t  i s  
becoming more clear that autophagy does not always 
represents a mechanism for cell death, but it can also 
be a mechanism for cell survival since it mediates the 
clearance of unhealthy intracellular compartments 
(diminishing the intracellular damage) and it can 
minimize the metabolism of cells when they are under 
stress conditions. Thus, it remains to be clarified 
whether the role of p38 MAPK in autophagy is indeed 
associated with cell death or cell survival. 
As an important note, most studies cited above 
were performed using pharmacological inhibitors of 
p38 MAPK to address the role of this pathway in cell 
survival or cell cycle checkpoint. While these com-
pounds are relatively specific for p38 MAPK, this 
specificity is strictly determined by the used concen-
tration. Studies exclusively based in the use of high 
concentrations (≤ 10 μM) of these compounds may be 
misleading since at high concentrations the p38 MAK 
inhibitors also interfere with other MAPKs such as 
JNK, and the JNK signaling pathway can also provide 
survival in specific situations [71, 72]. Only studies 
using different acceptable doses of the p38 MAPK 
inhibitors, or in combination with genetic studies 
have been considered in this review. Future studies 
using conditional knockout mice for the different p38 
MAPK family members will be important to further 
corroborate the current conclusions. 
Remarks 
  In summary, in addition to the 
well-characterized role of the p38 MAPK in cell death 
and differentiation, we have described here the con-
tribution that this signaling pathway also has to cell 
survival and the initiation/maintenance of cell cycle 
checkpoints in response to specific stimuli. It is im-
portant to be aware of these other alternative func-
tions of p38 MAPK considering that pharmacological 
inhibitors of p38 MAPK have been and are still being 
developed by a large number of corporations with a 
therapeutic purpose. While these compounds are be-
ing designed primarily for treatment of autoimmune 
disease such as rheumatoid arthritis, the role of p38 
MAPK providing survival to tumor cells suggests that 
these drugs could also be used as anti-tumor agents in 
combination with other classical chemotherapeutic 
drugs. As mentioned above, additional studies using 
genetic approaches are urgently needed to confirm 
the conclusions obtained from the use of inhibitors in 
vitro. It also remains to be defined the specific mecha-
nisms used by p38 MAPK to mediate survival and the 
cell cycle checkpoints, and how p38 MAPK discrimi-
nates its targets to mediate cell death from those to 
mediate cell survival. Although most studies have 
focused on p38α MAPK, it is important to better un-
derstand the contribution of the other p38 MAPK 
family members, and how these complement or com-
pensate each other.  
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